In the recent years, the medical reform has taken the center stage in China and a great amount of efforts has poured in. In an attempt to reduce the high drug price and improve its medical insurance coverage, China has initiated a series of new moves, including the most recent zero import tax on a …
The dramatic changes in lifestyle and aging population have expedited the spread of diabetes in the past decade. According to statistics, there was a total of 425 million adults with diabetes worldwide last year. And the incidence rate was as high as 8.8% (from 20 to 79 years old). It is predicted that the diabetes …
In the face of high tariffs, multiple layers of distribution, and monopoly supply, imported drugs have been extremely expensive in China. And this issue especially affects imported anticancer medications, which, compared with their counterparts abroad, are normally priced 2–3 times, sometimes even five times higher in China. An increasing number of Chinese patients are forced …
Since its approval as the first PD-1/PD-L1 inhibitor, on September 4, 2014, Keytruda has stood on the top of the heap and dominated attention across the spectrum of industry watchers. At present, the competition in this field is especially fierce. All five PD-1/PD-L1 inhibitors on the market are actively expanding their territories and rapidly pushing …
Across the globe, many countries have pegged big hopes on biosimilars. The situation is no different in China. In the face of the supportive pharmaceutical industry policies, the biosimilar drug development in China is riding on an upward trend. However, compared to the advanced US and European market, China still has plenty of room to …
On March 12, 2018 the Chinese FDA (CFDA) approved the clinical trial application of LCAR-B38M CAR-T cell self-reinfusion preparation from Nanjing Legend Biotech, marking the first cellular therapy to officially enter the clinical trial stage in China. LCAR-B38M is targeted at B-cell maturation antigen (BCMA), a member of TNF receptor family and also an extremely …
For the majority of traditional pharma companies, 2017 was a tough year. A round of new policies repeatedly challenged and changed the industry status quo. For innovative pharmas, however, it was different story – a year full of hopes and opportunities. Thanks to the steady increase in healthcare need, the introduction of policies favorable to …
A deep dive of the Chinese pharmaceutical industry in 2017 Once again, it is the time to do a deep dive of the Chinese pharmaceutical industry in 2017. Recently, East Money Information has published their latest Chinese top 500 company list for the past year. Among them, 42 pharmaceutical companies have the honor to join …
An overview of the new progress in the pharmaceutical industry in 2017 In this article, I detailed 3 breakthroughs in the pharmaceutical industry in 2017. Breakthrough of “0”: On 2 June 2017, China formally became a member of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), marking …
The Chinese innovative medicine field is marching into a new phase. The number of novel drugs has exploded in the past few years and is riding on a steady upward trend. It is predicted that 15 to 20 new drugs will be approved from 2018 to 2020, at a speed of 4 to 5 per …